Article Text

Download PDFPDF
247 Association of VEGF-1154 G/A polymorphism with clinicopathological parameters in ovarian cancer
  1. Nadia Boujelbene1,
  2. Ines Zemni2,
  3. Sana Baroudi3,
  4. Wafa Babay3,
  5. Taheni Hnihina3,
  6. Mohamed Ali Ayadi2,
  7. Imen Ouzari3 and
  8. Ines Zidi3
  1. 1Department of Pathology, Salah Azaïz Institute, Faculty of Medicine, Tunis, Tunisia
  2. 2Department of Surgical Oncology, Salah Azaïz Institute, Faculty of Medicine, Tunis, Tunisia
  3. 3Laboratory Microorganisms and Active Biomolecules, Sciences Faculty of Tunis, University Tunis El Manar, Tunis, Tunisia


Introduction/Background Most patients with ovarian cancer are diagnosed at an advanced stage leading to poor outcomes. Among the important molecular factors, vascular endothelial growth factor (VEGF) has become a key factor in angiogenesis, an important process in cancer development. We aimed to investigate the association between the VEGF -1154 G/A polymorphism and clinicopathological parameters of ovarian cancer.

Methodology The study included 29 patients diagnosed with ovarian carcinoma and 36 women healthy controls. The genotyping of the -1154 G/A polymorphism (rs1570360) was conducted by PCR-SSP. Clinicopathological parameters included age, tumor stage, and histological type. All statistical analyses were performed using the GraphPad Prism software.

Results Comparative analysis revealed a significant increase in the prevalence of the G allele (77.59%) in patients compared with controls (52.86%) suggesting its possible association with the occurrence of ovarian cancer (OR=3.087, 95% CI=[1.422–6.705], p=0.0037). Furthermore, analysis of genotype distribution showed statistically significant differences between patients and controls, with the G/G genotype being more prevalent in patients (72.41%) compared with controls (25.71%). Additionally, the frequency of the G/G genotype in patients is significantly higher than that of the combined G/A and A/A genotypes (p=0.0002), suggesting that G/G could be a risk factor for ovarian cancer (OR=7.583, 95% CI=[2.492–23.070]). Conversely, the G/A genotype frequency is higher in the control group suggesting its potential protective role against ovarian cancer (OR=0.097, 95% CI=[0.028–0.367], p=0.0002). The analysis according to clinicopathological parameters reveals that the G allele is more common in late stages (III+IV) than in early stages (I+II). The G/G genotype was underrepresented at early stages, suggesting a potential association with tumor progression.

Conclusion Our study provides convincing evidence of a potential association between the VEGF -1154 G/A polymorphism and clinicopathological parameters in ovarian cancer. These findings highlight the importance of genetic factors in influencing disease progression.

Disclosures The authors certify that there is no conflict of interest to declare.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.